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Abstract
Human mammary epithelial cells (HMECs) exhibit an
increase in phosphocholine (PC) and total choline-
containing compounds, as well as a switch from high
glycerophosphocholine (GPC)/low PC to low GPC/high
PC, with progression to malignant phenotype. The
treatment of human breast cancer cells with a non-
steroidal anti-inflammatory agent, indomethacin, re-
verted the high PC/low GPC pattern to a low PC/high
GPC pattern indicative of a less malignant phenotype,
supported by decreased invasion. Here, we have
characterized mechanisms underlying indomethacin-
induced alterations in choline membrane metabolism
in malignant breast cancer cells and nonmalignant
HMECs labeled with [1,2-13C]choline using 1H and 13C
magnetic resonance spectroscopy. Microarray gene
expression analysis was performed to understand the
molecular mechanisms underlying these changes. In
breast cancer cells, indomethacin treatment activated
phospholipases that, combined with an increased cho-
line phospholipid biosynthesis, led to increased GPC
and decreased PC levels. However, in nonmalignant
HMECs, activation of the anabolic pathway alone was
detected following indomethacin treatment. Following
indomethacin treatment in breast cancer cells, several
candidate genes, such as interleukin 8, NGFB, CSF2,
RHOB, EDN1, and JUNB, were differentially expressed,
which may have contributed to changes in choline me-
tabolism through secondary effects or signaling cas-
cades leading to changes in enzyme activity.
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Introduction
Proton and 31P magnetic resonance spectroscopy (MRS)
studies have detected high levels of phosphocholine (PC),
phosphoethanolamine (PE), or both in most cancers, includ-
ing breast cancer, whereas low levels of these metabolites
have been found in corresponding normal tissues [1]. Con-
sistently elevatedPCandPE levelswere observed in human
breast cancer cells in culture [2,3], with PC and total choline-
containing compounds (tCho) progressively increasingwithma-
lignancy [3]. An increased malignancy of breast cancer cells
also resulted in higher levels of PC relative to glycerophospho-
choline (GPC), as reflected by an increased PC/GPC ratio [3].
These increased PC levels in breast cancer cells can be at-
tributed to an increased expression and/or activity of choline
kinase [4,5], phospholipase D (PLD), or phospholipase C (PLC)
[5,6], and/or to increased choline transport [7]. Transfection of
malignant breast cancer cells by the metastasis-suppressor
gene nm23 significantly decreased the PC/GPC ratio [8],
whereas an increase in PC levels was detected in NIH 3T3
cells transfected with the mutant ras oncogene [9], providing
further evidence of a close link between choline phospholipid
metabolites and malignancy. Treatment with antimicrotubule
drugs significantly increased cellular GPC levels in several
breast cancer cell lines [10], as did treatment with the non-
steroidal anti-inflammatory agent, indomethacin [11,12]. Indo-
methacin increased GPC levels and decreased PC levels in
breast cancer cells and in nonmalignant human mammary epi-
thelial cells (HMECs). These data suggest that diverse genes
and drugs profoundly alter choline phospholipid metabolism
and result in common endpoints of change in PC and GPC.
The increase of GPC and the decrease of PC in indomethacin
treatment suggest that choline compounds may be linked to
inflammatory pathways [11,12]. Brain 1H MRS studies of mul-
tiple sclerosis (MS) have demonstrated that an elevated choline
signal was observed in inflammatory disease states [13]. Proton
MRS of neuroblastoma cells treated with cyclooxygenase
(COX) inhibitors demonstrated depletion of choline compounds
[14]. Indomethacin is a nonsteroidal anti-inflammatory drug
(NSAID) and a nonspecific COX (EC 1.14.99.1) inhibitor. Indo-
methacin inhibits COX-1 and COX-2 time-dependently by
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noncovalently binding to the COX active site [15]. Treatment
with indomethacin reduces the invasive and metastatic be-
haviors of human breast cancer cells [16]. Indomethacin was
also shown to reduce angiogenesis [17] and tumor growth [18].
In normal tissues, arachidonic acid, a key mediator of
inflammation, is released from membrane phosphatidyl-
choline (PtdCho) by phospholipase A2 (PLA2) (Figure 1) in
response to tissue injury. Two isoforms of COX, COX-1 and
COX-2, catalyze the conversion of arachidonate to prosta-
glandin endoperoxide H2 (PGH2) in a two-step reaction: by
acting as a COX and then by exhibiting peroxidase activity.
PGH2 is used as an immediate substrate for a series of cell-
specific prostaglandin and thromboxane synthases, which
eventually synthesize different eicosanoids [19,20]. The con-
stitutive form of COX, COX-1, is significantly overexpressed
in malignant versus nonmalignant HMECs [11]. The induc-
ible form of COX, COX-2, which is regulated by cytokines,
growth factors, tumor promoters, and hypoxia, was shown
to have high expression levels in a wide variety of human
and animal tumors [21]. Increasing evidence suggests that
COX-2 overexpression is caused by disturbances of cellular
signaling cascades, such as the Ras–Raf–MAPkinase cas-
cade, due to oncogenic gene mutations [21].
Recently, it was shown that the effect of indomethacin on
choline metabolite profile in HMECs may be partly mediated
through the upregulation of the metastasis-suppressor gene
nm23 [11]. Previous studies have demonstrated the utility of
[1,2-13C]choline, in combination with 13CMRS, to the study of
choline metabolism [5,22]. In this study, the 1H and 13C MRS
of HMECs labeled with [1,2-13C]choline was performed to
further understand the mechanisms underlying the increase
of GPC relative to PC, following treatment with indomethacin
in breast cancer cells and HMECs. The spontaneously im-
mortalized nonmalignant HMEC line MCF-12A was com-
pared with the estrogen receptor–negative, highly invasive,
and metastatic human breast cancer line MDA-MB-231.
Long-term and short-term incubations with [1,2-13C]choline
were performed to distinguish between the anabolic and
catabolic pathways of choline metabolism, as previously de-
scribed [5]. A microarray-based gene expression analysis
with the Human Genome U133 Set (Affymetrix, Inc., Santa
Clara, CA) was performed to probe more than 39,000 tran-
scripts derived from approximately 33,000 well-substantiated
human genes [5]. This microarray analysis using the Affy-
metrix set was used to determine changes in gene expres-
sion profiles between control and indomethacin-treated
MCF-12A HMECs and MDA-MB-231 breast cancer cells.
Methods
Cell Lines
The spontaneously immortalized nonmalignant HMEC
line MCF-12A, established from MCF-12M mortal cells [23],
Figure 1. Biosynthetic (solid lines) and catabolic (dashed lines) enzymatic reactions in PtdCho and arachidonic acid metabolism. CDP, cytosine diphosphate;
CMP, cytosine monophosphate; CTP, cytosine triphosphate; PPi, pyrophosphate.
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was obtained from the American Type Culture Collection
(Rockville, MD) and was cultured in DMEM–Ham’s F12 me-
dium (Invitrogen Corporation, Carlsbad, CA), supplemented
as described previously [5,23]. The invasive and metastatic
humanmammary epithelial cancer cell line MDA-MB-231 was
provided by Dr. R. J. Gillies (Arizona Health Sciences Center,
Tucson, AZ) and was maintained in RPMI 1640 medium
(Invitrogen Corporation), supplemented with 10% fetal bovine
serum, 100 U/ml penicillin, and 100 mg/ml streptomycin (Invi-
trogen Corporation), as previously described [5].
Incubation and Dual-Phase Extraction
MCF-12A and MDA-MB-231 cells were cultured to 60%
confluency. Long-term (24 +3 hours) and short-term (3 hours)
labeling experiments with 100 mM [1,2-13C]choline (99% 13C-
enriched; Cambridge Isotope Laboratories, Inc., Andover,
MA) were performed for both cell lines, as previously de-
scribed [5]. This approach enabled us to distinguish between
the anabolic pathway and the catabolic pathway in PtdCho
metabolism because, in long-term experiments, the mem-
brane PtdCho pool of cells became partially enriched with
13C, whereas in short-term experiments, the duration of
exposure to the labeled substrate was not long enough for
the labeling of the PtdCho pool. As a result, cells in short-term
experiments contained an unlabeled membrane PtdCho
pool. For long-term experiments, cells were exposed to a
fresh cell culture medium containing 100 mM [1,2-13C]choline
for 24 hours to build up the prelabeled PtdCho pool, followed
by a 3-hour experimental incubation period. For short-term
experiments, cells were incubated with a fresh medium
containing 100 mM unlabeled choline for 24 hours during
the prelabeling period. Following the prelabeling incuba-
tion period, we performed experimental incubations. For the
indomethacin-treated group, cells were incubated with 300 mM
indomethacin in a medium containing 100 mM [1,2-13C]choline
for 3 hours. Control cells were incubated for 3 hours with
a [1,2-13C]choline medium alone during the experimental
incubation period. Before cells were harvested and extracted,
they were washed thrice, each with 10 ml of phosphate-
buffered saline. Approximately 108 cells were harvested,
and both lipid-soluble and water-soluble cell extract fractions
were obtained using a dual-phase extraction method, as pre-
viously described [5,24]. Briefly, circa 108 cells per extract
were harvested by trypsinization, washed twice with 10 ml of
saline at room temperature, and pooled into a glass centri-
fuge tube. Cells were counted for quantitation directly after
trypsinization. Four milliliters of ice-cold methanol was added
to the cells, vigorously vortexed, and kept on ice for 10 min-
utes. Four milliliters of chloroform was added and vigorously
vortexed. Finally, 4 ml of water was added, and the sample
was vortexed and left overnight at 4jC for phase separation.
The samples were centrifuged for 30 minutes at 35,000g at
4jC, and phases were carefully separated. The water–
methanol phase containing water-soluble cellular metabo-
lites was treated with 10mg of Chelex for 10minutes on ice to
remove divalent cations. Chelex beads were then removed.
Methanol was removed by rotary evaporation. The remaining
water phases were lyophilized and stored at 20jC. The
chloroform phase containing cellular lipids was dried in a
stream of N2 and stored under N2 at 20jC [5].
Data Acquisition and Processing
Water-soluble samples were dissolved in 0.5 ml of D2O
(Sigma-Aldrich, St. Louis, MO) containing 0.24 106 mol of
3-(trimethylsilyl)propionic-2,2,3,3,-d4 acid (TSP; Sigma-
Aldrich) as an internal concentration standard (sample pH
of 7.4). Lipid samples were dissolved in 0.6 ml of CDCl3/
CD3OD (2/1, vol/vol) containing 2.17  106 mol of tetrame-
thylsilane (TMS) as an internal concentration standard
(CDCl3 and CD3OD were premixed with TMS by the manu-
facturer, Cambridge Isotope Laboratories, Inc.) [5]. High-
resolution proton-decoupled 13C and fully relaxed 1H MR
spectra of all samples were acquired on a Bruker MSL-500
spectrometer operating at 11.7 T (Bruker BioSpin Corpora-
tion, Billerica, MA), as previously described [5]. Fully relaxed
1H MR spectra without saturation effects were obtained at
500 MHz using a 5-mm HX inverse probe, with flip angle =
30j, sweep width = 6000 Hz, repetition time = 12.7 seconds,
block size = 32,000, and scans = 128. Composite pulse
(WALTZ-16) proton-decoupled 13C MR spectra were
recorded at 125.7 MHz using a 10-mm BB probe, with flip
angle = 30j, sweep width = 29,411 Hz, repetition time =
3 seconds, block size = 16,000 (zero filling to 32,000), and
scans = 20,000 (water-soluble metabolites) or 6000 (lipids).
Carbon-13 MR spectra were corrected for saturation and nu-
clear Overhauser effects, as previously described [5]. MR
spectra were analyzed using an in-house software program,
Soft Fourier Transform (P. Barker, Johns Hopkins University
School of Medicine, Baltimore, MD), as previously described
[5]. Proton spectra were zero-filled and Fourier-transformed,
and signal integrals were measured by frequency-domain
fitting in Soft Fourier Transform. Carbon-13 spectra were pro-
cessed using a line broadening of 1.5 Hz (zero-filled and
Fourier-transformed), and signal integrals were computed in
Soft Fourier Transform. The signals of TSP (water-soluble
metabolites) or TMS (lipids) served as references for chem-
ical shift and concentration in 1H MR spectra. The signal
integrals of the N–(CH3) 3 signals of free choline (Cho) at
3.209 ppm, of PC at 3.227 ppm, and of GPC at 3.236 ppm in
the 1H MR spectra of water-soluble metabolites, as well as
the N–(CH3) 3 signal of PtdCho at 3.22 ppm in the
1H MR
spectra of lipids, were determined and normalized according
to cell size and number, as previously described [3,5], using
the following equation:
½metabolite ¼ Imetabolite  standard
Istandard  cell number cell volume
In this equation, [metabolite] represents the intracellular
concentration of the metabolite of interest (in mM); Imetabolite
represents the signal integral of the metabolite of interest
divided by the number of protons; and Istandard represents the
amount of TSP (water-soluble metabolites) or TMS (lipids)
used (in mol) divided by the number of protons. The number
of cells in each sample (cell number) was counted before
extraction, and the cell volume values used were determined
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previously for MCF-12A and MDA-MB-231 cells [3,5]. Long-
term and short-term [1,2-13C]choline exposure experiments
did not significantly alter the total metabolite concentrations,
as quantitated from 1H MR spectra. Therefore, data from
these experiments were pooled.
Carbon-13 MR spectra of water-soluble metabolites were
referenced to the lactate C3 signal at 21.3 ppm. Lipid 13C MR
spectra were calibrated using the solvent signal of deuterated
methanol at 49.5 ppm. The corrected 13C signal integral of
the N–(CH3)3 group signal at 55.0 to 55.2 ppm was used as
a reference to calculate the specific 13C enrichment of Cho,
PC, GPC, and PtdCho. This was possible because the
corrected 13C signal integral of the N–(CH3)3 group con-
tained only the naturally abundant 13C signal contribution of
Cho + PC + GPC (water-soluble metabolites) or PtdCho
(lipids). The N–(CH3)3 group signal was chosen for this
purpose because it was detected in the 1H MR spectra, as
well as in the 13C MR spectra. The calculation of specific
fractional 13C enrichments was performed with the signals of
GPC, PC, and Cho within the O–CH2 region because, unlike
the N–CH2 region, there was no signal overlap in this region.
Both signals of PtdCho were used for analysis in the lipid
13C MR spectra. Fractional 13C enrichments were calculated
from corrected 13C signal integrals of Cho, PC, GPC, and
N–(CH3)3 in the spectra of water-soluble metabolites, and
from PtdCho and N–(CH3)3 in the lipid spectra, according to
the following equation:
fractional 13C enrichmentmetabolite
¼ I13Cmetabolite I1HðNðCH3Þ3Þ  0:0107
I13CðNðCH3Þ3ÞI1Hmetabolite
In this equation, 13C enrichmentmetabolite represents the
fractional 13C enrichment within the total pool of the metab-
olite of interest; I13Cmetabolite represents the signal integral of
the metabolite of interest in the 13C MR spectrum divided by
the number of carbons; I1HðNðCH3Þ3Þ represents the signal in-
tegral of the N–(CH3)3 signal of (Cho + PC +GPC) or PtdCho
in the 1H MR spectrum divided by the number of protons;
I13CðNðCH3Þ3Þ represents the signal integral of the naturally
abundant N–(CH3)3 signal of (Cho + PC + GPC) or PtdCho
at 55.0 to 55.2 ppm divided by the number of carbons; and
I1Hmetabolite represents the signal integral of the metabolite
of interest in the 1H MR spectrum divided by the number
of protons [5].
RNA Isolation, GeneChip Microarray Assay, and Microarray
Data Analysis
Total cellular RNA was isolated from approximately
107MDA-MB-231 orMCF-12A cells after 2 hours of treatment
with 300 mM indomethacin, as well as from MDA-MB-231
or MCF-12A cells incubated under control conditions for
2 hours, using the RNeasy Mini Kit (Qiagen, Inc., Valencia,
CA) and QIAshredder homogenizer spin columns (Qiagen,
Inc.), as previously described [5]. We chose a 2-hour indo-
methacin incubation period for microarray experiments be-
cause we anticipated that changes in gene expression levels
would occur at a time point slightly earlier than that of
metabolic changes (where indomethacin treatment was per-
formed for 3 hours) because gene expression changes
would translate into metabolic effects later. Microarray hy-
bridization was performed at the JHMI Microarray Core
Facility (Dr. Francisco Martinez Murillo, Johns Hopkins Uni-
versity School of Medicine) using the Human Genome U133
Set consisting of two GeneChip arrays (Affymetrix, Inc.) and
the Affymetrix GeneChip platform [5]. The Human Genome
U133 GeneChip Set contains approximately 45,000 probe
sets representing 39,000 transcripts. GeneChip was ana-
lyzed by fluorescence detection using the Agilent GeneArray
Scanner (Agilent Technologies, Inc., Palo Alto, CA). Data
acquisition was performed using the Micro Array Suite 5.0
software (Affymetrix). Experiments were performed in dupli-
cate. To estimate gene expression signals, data analysis was
conducted on the chips’ cell intensity file probe signal values
at the Affymetrix probe pair (perfect match probe and mis-
match probe) level, using statistical techniques and the
package Robust Multiarray Analysis [25]. This probe-level
data processing includes a normalization procedure using
quantile normalization [26] to reduce obscuring variation
between microarrays, which might be introduced during the
processes of sample preparation, manufacture, fluorescence
labeling, hybridization, and/or scanning. Using signal inten-
sities as estimated above, an empirical Bayes method with
log-normal–normal modeling, as implemented in theR pack-
age EBarrays, was used to estimate the posterior probabil-
ities of the differential expression of genes between
indomethacin-treated and control samples [27]. The criterion
of the posterior probability > .5, which means that the poste-
rior probability is larger than chance, was used to produce
differentially expressed gene lists. All computations were
performed under the R environment.
Statistical Analysis
A two-tailed t-test (a = 0.05) was used to detect any sig-
nificant differences between the control and the indomethacin-
treated groups. Because identical results were obtained
in the 1H MR spectra of long-term (n = 3) and short-term
(n = 3) [1,2-13C]choline exposure, 1H MR data from these
experiments were pooled to give n = 6. P < .05 was con-
sidered significant.
Results
Distinct differences in choline metabolism were detected
following treatment with indomethacin. Typical 13C MR spec-
tra following long-term (a) or short-term (b) exposure to
[1,2-13C]choline and the corresponding 1H (c) MR spectra
of the water-soluble metabolites obtained from control
(lower panel ) and indomethacin-treated (upper panel) MDA-
MB-231 human breast cancer are displayed in Figure 2.
Treatment with 300 mM indomethacin for 3 hours significantly
(P < .01) decreased the PC/GPC ratio in both MCF-12A and
MDA-MB-231 cells (Figures 2c and 4a). This decrease in the
PC/GPC ratio could result from a net decrease in PC levels,
combined with a net increase in GPC levels, as observed in
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the 1H MR spectra of long-term and short-term experiments
(Figures 2c and 4a; n = 6). Free cellular choline levels (Cho)
significantly (P < .05) increased in the breast cancer cell
line, but not in HMECs (Figures 2c and 4a; n = 6). Levels of
tCho (Cho + PC + GPC) remained constant following indo-
methacin treatment in HMECs and breast cancer cells. 13C
enrichment in the GPC pool remained constant following
indomethacin treatment during long-term experiments (Fig-
ures 2a and 4b; n = 3) in both HMECs and breast cancer
cells. No 13C enrichment in GPCwas detected following indo-
methacin treatment in short-term experiments (Figure 2b)
in either of the cell lines. 13C enrichment of the PC pool
remained relatively constant in indomethacin-treated HMECs
and breast cancer cells compared to corresponding control
cells in long-term experiments (Figures 2a and 4b; n = 3). In
short-term experiments, however, 13C enrichment of the PC
pool significantly (P < .05) decreased following treatment
in the breast cancer cell line, whereas it remained constant
in nonmalignant HMECs (Figures 2b and 4b; n = 3). The
increase in Cho following indomethacin treatment in MDA-
MB-231 breast cancer cells was detected in the 13C MR
spectra of long-term experiments (Figures 2a and 4b) and by
1H MRS (Figures 2c and 4a), but not in the 13C MR spectra of
short-term experiments (Figures 2b and 4b). In contrast, no
increased Cho levels were detected in the nonmalignant
HMEC line MCF-12A following indomethacin treatment
(Figure 4a). 13C enrichment in the membrane PtdCho pool of
long-term experiments was significantly (P < .05) increased
following indomethacin treatment in HMECs (Figure 4b) and
was slightly increased in breast cancer cells (Figures 3a and
4b). 13C enrichment of the membrane PtdCho in short-term
experiments was not detected in control or indomethacin-
treated cells (Figure 3b).
Indomethacin treatment resulted in several changes in
gene expression, which were different for MCF-12A HMECs
and humanMDA-MB-231 breast cancer cells, as detected by
Figure 2. Representative (a) long-term 13C, (b) short-term 13C, and (c) 1H MR spectra of the water-soluble fractions of control MDA-MB-231 breast cancer cells
(bottom panel) and MDA-MB-231 cells treated with 300 M indomethacin for 3 hours (top panel). Cells were labeled with 100 M [1,2-13C]choline for 24 + 3 hours in
long-term experiments and for 3 hours in short-term experiments. MR, magnetic resonance.
Figure 3. Representative (a) long-term 13C and (b) short-term 13C MR spectra of the lipid fractions of control MDA-MB-231 breast cancer cells (bottom panel) and
MDA-MB-231 cells treated with 300 M indomethacin for 3 hours (top panel). Cells were labeled with 100 M [1,2-13C]choline for 24 + 3 hours in long-term
experiments and for 3 hours in short-term experiments. MR, magnetic resonance.
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mRNA analysis using Affymetrix human genome U133 A/B
GeneChip combined with statistically modeled probe-level
data analysis [25–27]. The Affymetrix U133 A/B GeneChip
set contains all known genes of enzymes involved in choline
phospholipid metabolism (Figure 1, Table 1), except the
genes for GPC phosphodiesterase, which have not yet been
discovered. Indomethacin significantly altered the gene ex-
pression of 151 genes in MCF-12A HMECs and of 52 genes
in MDA-MB-231 breast cancer cells, using a posterior prob-
ability of > .5. No significant changes in gene expression
levels of genes/proteins directly involved in choline phospho-
lipid metabolism or choline transport, which were contained
in the Affymetrix U133 A/B GeneChip set and are listed in
Table 1, were detected in indomethacin-treated MCF-12A or
MDA-MB-231 cells. All significantly differentially expressed
genes were sorted by biologic function and are shown in
Table 2 for MCF-12A HMECs and in Table 3 for human
MDA-MB-231 breast cancer cells.
Genes given in the category ‘‘choline phospholipid me-
tabolism’’ in Tables 2 and 3 show differentially expressed
genes in MCF-12A and MDA-MB-231 cells, respectively, that
can interact with choline phospholipid metabolism, but do not
represent genes directly encoding enzymes in choline phos-
pholipid metabolism. In MCF-12A HMECs, mRNA expres-
sion of protein tyrosine phosphatase nonreceptor type 12
(PTPN12), mitogen-activated protein kinase kinase kinase
kinase 4 (MAP4K4), protein kinase C L (PRKCI ), UDP glu-
cose ceramide glucosyltransferase (UGCG), and junB proto-
oncogene (JUNB) was significantly decreased, which may
have affected choline phospholipid metabolism (Table 2). In
human MDA-MB-231 breast cancer cells, interleukin (IL)
8 was significantly underexpressed, whereas JUNB, ras ho-
molog gene family member B (RHOB), endothelin-1 (EDN1),
colony-stimulating factor-2 (CSF2), and nerve growth factor
beta (NGFB) polypeptide were significantly overexpressed
and may have impacted on choline phospholipid metabolism
(Table 3). JUNB was the only common choline phospholipid
metabolism–related gene that was upregulated in both
MCF-12A and MDA-MB-231 cells. JUNB overexpression
was more pronounced in MDA-MB-231 breast cancer cells
(3.265-fold, P = 1.000) compared to MCF-12A HMECs
(1.578-fold, P = .615).
Indomethacin treatment significantly altered only seven
identical genes in both MCF-12A HMECs and MDA-MB-231
breast cancer cells: JUNB (increase), PLK2 (decrease),
KLF4 (increase), TOB1 (decrease), ANGPTL4 (increase),
PPM2C (decrease), and BHLHB2 (increase). The magni-
tudes and directions in changes in these genes were rela-
tively comparable in MCF-12A and MDA-MB-231 cells.
Discussion
NSAIDs, such as indomethacin, are commonly used to
reduce tumor-induced suppression of the immune system,
to increase the effectiveness of anticancer drugs, and to
improve the quality of pain control. NSAIDs also have a clear
potential for use in the chemoprevention and treatment
of breast cancer [28]. Indomethacin has been shown to
Figure 4. (a) PtdCho, Cho, PC, and GPC levels and PC/GPC ratios in indomethacin-treated MCF-12A HMECs (striped black bars) versus control MCF-12A cells
(solid black bars), and indomethacin-treated MDA-MB-231 breast cancer cells (striped gray bars) versus control MDA-MB-231 cells (solid gray bars) quantified
from 1H MR spectra (n = 6). (b) Quantitation of the fractional 13C enrichment in PC, GPC, and PtdCho from long-term experiments (n = 3) and short-term
experiments (n = 3) in indomethacin-treated (striped black bars) and control (solid black bars) MCF-12A HMECs, and indomethacin-treated (striped gray bars) and
control (solid gray bars) MDA-MB-231 breast cancer cells. Cho, free choline; GPC, glycerophosphocholine; INDO, indomethacin-treated; MR, magnetic resonance;
PC, phosphocholine; PtdCho, phosphatidylcholine. Values represent mean ± SD. *P < .05, **P < .01, indomethacin-treated versus control.
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improve immune response [29], to prevent tumor angio-
genesis [29], to enhance apoptotic cell death [30], and to re-
duce tumor cell invasiveness and metastases [16].
Treatment with indomethacin resulted in significantly
decreased PC/GPC ratios in both nonmalignant HMECs
and highly malignant human breast cancer cells, which is in
excellent agreement with previously obtained results [11,12].
The decrease in the PC/GPC ratio was caused by a net
decrease in PC levels and a net increase in GPC levels, as
previously established [11,12]. The level of tCho, which
increases with malignant transformation [3] and is a poten-
tial diagnostic marker for breast cancer [31], was largely
unaffected by indomethacin. In addition to these findings,
which are consistent with our previous studies, indomethacin
treatment significantly increased Cho levels in breast cancer
cells but not in nonmalignant HMECs.
Short-term [1,2-13C]choline exposure resulted in unde-
tectable 13C enrichment in GPC, and enrichment in GPC in
long-term experiments remained constant following indo-
methacin treatment. Thus, the net increase in GPC following
Table 1. Genes of Enzymes Involved in Choline Transport and Choline Phospholipid Metabolism Contained in the Affymetrix Human Genome U133 Set.
Enzyme Type Gene Title Gene Symbol Representative
Public ID
Choline kinase Choline kinase alpha CHKA AI991328
Choline kinase alpha CHKA NM_001277
Choline kinase beta CHKB NM_005198
Diacylglycerol
cholinephosphotransferase
Choline phosphotransferase 1 CHPT1 AF195624
Lysophospholipase Lysophospholipase 3 (lysosomal PLA2) LYPLA3 AL110209
Lysophospholipase I LYPLA1 AF077198
Lysophospholipase I LYPLA1 BG288007
Lysophospholipase II LYPLA2 AK024724
Lysophospholipase II, lysophospholipase II pseudogene 1 LYPLA2, LYPLA2P1 AL031295
Lysophospholipase II, lysophospholipase II pseudogene 1 similar to




CTP: PC cytidylyltransferase Phosphate cytidylyltransferase 1, choline, alpha PCYT1A NM_005017
Phosphate cytidylyltransferase 1, choline, beta PCYT1B NM_004845
Phosphate cytidylyltransferase 1, choline, beta PCYT1B AF148464
PLA2 PLA2, group IB (pancreas) PLA2G1B NM_000928
PLA2, group IIA (platelets, synovial fluid) PLA2G2A NM_000300
PLA2, group IID PLA2G2D NM_012400
PLA2, group IIE PLA2G2E NM_014589
PLA2, group IIF PLA2G2F NM_022819
PLA2, group III PLA2G3 NM_015715
PLA2, group IVA (cytosolic, calcium-dependent) PLA2G4A M68874
PLA2, group IVB (cytosolic) PLA2G4B NM_005090
PLA2, group IVB (cytosolic) PLA2G4B AK000550
PLA2, group IVC (cytosolic, calcium-independent) PLA2G4C AF065214
PLA2, group V PLA2G5 NM_000929
PLA2, group V PLA2G5 AL158172
PLA2, group V PLA2G5 AL158172
PLA2, group VI (cytosolic, calcium-independent) PLA2G6 NM_003560
PLA2, group VI (cytosolic, calcium-independent) PLA2G6 AF102988
PLA2, group VI (cytosolic, calcium-independent) PLA2G6 AK001290
PLA2, group VII (platelet-activating factor acetylhydrolase, plasma) PLA2,
group VII (platelet-activating factor acetylhydrolase, plasma)
PLA2G7 NM_005084
PLA2, group X PLA2G10 NM_003561
PLA2, group XIIA, PLA2, group XIIA PLA2G12A NM_030821
PLD PLD1, phophatidylcholine-specific PLD1 NM_002662
PLD1, phophatidylcholine-specific PLD1 AJ276230
PLD1, phophatidylcholine-specific PLD1 AJ276230
Choline transport Solute carrier family 22 (extraneuronal monoamine transporter), member 3 SLC22A3 NM_021977
Solute carrier family 22 (organic anion transporter), member 6 SLC22A6 AF124373
Solute carrier family 22 (organic anion transporter), member 6 SLC22A6 AJ271205
Solute carrier family 22 (organic anion transporter), member 7 SLC22A7 NM_006672
Solute carrier family 22 (organic anion transporter), member 7 SLC22A7 AF210455
Solute carrier family 22 (organic anion transporter), member 7 SLC22A7 AF210455
Solute carrier family 22 (organic anion transporter), member 7 SLC22A7 AA777852
Solute carrier family 22 (organic anion transporter), member 8 SLC22A8 NM_004254
Solute carrier family 22 (organic anion transporter), member 8 SLC22A8 AW025165
Solute carrier family 22 (organic cation transporter), member 1 SLC22A1 NM_003057
Solute carrier family 22 (organic cation transporter), member 13 SLC22A13 NM_004256
Solute carrier family 22 (organic cation transporter), member 14 SLC22A14 NM_004803
Solute carrier family 22 (organic cation transporter), member 16 SLC22A16 AL050350
Solute carrier family 22 (organic cation transporter), member 16 SLC22A16 AL050350
Solute carrier family 22 (organic cation transporter), member 2 SLC22A2 NM_003058
Solute carrier family 22 (organic cation transporter), member 4 SLC22A4 NM_003059
Solute carrier family 22 (organic cation transporter), member 5 SLC22A5 NM_003060
Solute carrier family 5 (choline transporter), member 7 SLC5A7 NM_021815
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Table 2. Significantly Differentially Expressed Genes Following Indomethacin Treatment in MCF-12A HMECs, by Function.
Function Gene Symbol Representative
Public ID
Fold Change Probability
Angiogenesis regulation ANGPTL4 AF169312 1.972 1.000
BTG1 AL535380 2.018 1.000
Apoptosis regulation ANGPTL4 AF169312 1.972 1.000
BTG1 AL535380 2.018 1.000
SON AA664291 1.610 .885
Biosynthesis ARG99 AU151239 1.486 .776
AMD1 NM_001634 1.567 .744
UGCG AI378044 1.539 .627
Cell adhesion DST NM_001723 1.722 .992
NRCAM NM_005010 1.584 .827
PKP4 NM_003628 1.584 .818
RAPH1 AA194149 1.475 .752
THBS1 AW956580 1.451 .579
Cell cycle regulation PLK2 NM_006622 2.783 1.000
182-FIP AW007746 1.685 .999
DST NM_001723 1.722 .992
CCNG2 L49506 1.677 .985
DNAJA2 AW057513 1.543 .943
CDKN1B BC001971 1.588 .771
E2F3 NM_001949 1.553 .712
Cell differentiation regulation BTG1 AL535380 2.018 1.000
Cell growth RBM15 NM_022768 1.555 .654
TMEFF2 AB004064 1.499 .586
Cell motility THBS1 AW956580 1.451 .579
Choline phospholipid metabolism PTPN12 S69182 1.672 .985
MAP4K4 NM_017792 1.591 .835
PRKCI AI689429 1.574 .781
UGCG AI378044 1.539 .627
JUNB NM_002229 1.578 .615
Chromosome organization CHD1 AU155298 1.516 .952
Coenzyme A biosynthesis PANK1 AI373299 1.636 .997
Cytokinesis ROCK2 AL049383 1.566 .762
Cytoplasmic regulation FUSIP1 AI954700 1.584 .985
Cytoskeleton regulation PRKCI AI689429 1.574 .781
Development GATA6 D87811 1.559 .775
THBS1 AW956580 1.451 .579
Differentiation MBNL1 BF512200 1.610 .926
NRCAM NM_005010 1.584 .827
DNA repair REV1L N51427 1.455 .572
Embryonic development MBNL1 BF512200 1.610 .926
Exonuclease activity FLJ12671 AW294587 1.573 .634
Immune response IL7 AW190593 1.518 .878
Ion homeostasis DKFZp434P0216 AW778829 1.491 .752
KCTD12 AI718937 1.638 .924
Metabolism GLS AI828035 1.509 .797
FLJ34658 AW173071 1.461 .683
TDG NM_003211 1.518 .551
Microtubule nucleation TUBGCP3 NM_006322 1.522 .548
Mitochondrial transport UCP2 U94592 2.045 1.000
mRNA processing CPSF6 AU149663 1.490 .772
Neuron development NRCAM NM_005010 1.584 .827
Not determined PAPD5 AI492902 1.802 1.000
C6orf52 AW001000 1.792 1.000
FLJ22490 AI400587 1.724 1.000
YTHDF3 AU157915 1.835 1.000
ARRDC3 AB037797 1.705 .999
VMP1 BF674052 1.687 .999
PDCD1LG1 AI608902 1.655 .998
WTAP AU147416 1.668 .992
MGC14289 AI188445 1.589 .986
C3orf6 AV683852 1.556 .972
FLJ20729 NM_017953 1.645 .962
TXNIP AI439556 1.697 .961
DKFZp451J1719 AI982535 1.547 .958
ZC3HAV1 AI133727 1.656 .958
C20orf158 AW664953 1.535 .945
LOC124512 AA883486 1.560 .941
YTHDF2 NM_016258 1.610 .893
EXOC8 AI168350 1.505 .854
ZCCHC7 BG291039 1.498 .853
ALS2CR4 AU150140 1.491 .798
NHSL1 AA503387 1.490 .770
Indomethacin Alters Choline Lipid Metabolism Glunde et al. 765
Neoplasia . Vol. 8, No. 9, 2006
Table 2. (continued)
Function Gene Symbol Representative
Public ID
Fold Change Probability
Not determined PHACTR2 AW880875 1.479 .745
KIAA0261 D87450 1.556 .714
HELLS AI807356 1.469 .677
HSPC063 AU144305 1.463 .675
LOC132671 AI559300 1.494 .662
LOC285338 BF691831 1.457 .638
KIAA0143 AA805651 1.550 .617
KIAA0853 BE895685 1.541 .604
NCOA6IP NM_024831 1.538 .593
AEBP2 BF475280 1.445 .589
FLJ20696 AI979334 1.456 .533
ACRBP AI141116 1.443 .509
Nucleoside metabolism UPP1 NM_003364 1.632 .815
Nucleotide excision repair RAD23B NM_002874 1.602 .694
Proliferation regulation KLF4 BF514079 2.771 1.000
BTG1 AL535380 2.018 1.000
TOB1 AA675892 1.671 .978
EDD U69567 1.640 .946
DNAJA2 AW057513 1.543 .943
IL7 AW190593 1.518 .878
CDKN1B BC001971 1.588 .771
Protein biosynthesis EIF1AX AL079283 1.675 .971
Protein dephosphorylation PTPN12 S69182 1.672 .985
PPM2C BG542521 1.585 .984
PPP4R2 AI983837 1.553 .964
Protein folding DNAJA2 AW057513 1.543 .943
DNAJC4 AW071239 1.517 .887
FLJ14281 AL121021 1.463 .607
SEC63 NM_007214 1.528 .555
Protein modification MGC10067 H73636 1.444 .505
Protein phosphorylation PLK2 NM_006622 2.783 1.000
LYN AI356412 1.739 .994
BMP2K AU145366 1.577 .980
MAP4K4 NM_017792 1.591 .835
PRKCI AI689429 1.574 .781
ROCK2 AL049383 1.566 .762
PRPF4B Z25435 1.575 .741
Protein transport IPO7 AI741392 1.701 .992
RANBP5 AU148466 1.565 .712
Protein ubiquitination EDD U69567 1.640 .946
FLJ31951 AL553942 1.601 .944
FBXW2 AL043967 1.577 .806
BAZ1A NM_013448 1.575 .774
PJA2 AA142966 1.545 .674
HACE1 AB037741 1.460 .633
Proton transport UCP2 U94592 2.045 1.000
Signal transduction PLK2 NM_006622 2.783 1.000
GDF15 AF003934 1.774 .997
LYN AI356412 1.739 .994
SOCS5 AW664421 1.678 .993
IPO7 AI741392 1.701 .992
IL7 AW190593 1.518 .878
PRKCI AI689429 1.574 .781
ROCK2 AL049383 1.566 .762
RAPH1 AA194149 1.475 .752
CREBL2 NM_001310 1.540 .530
RAPGEF6 AI640834 1.450 .511







Splicing regulation FUSIP1 AI954700 1.584 .985
SR140 AU152088 1.595 .842
PRPF4B Z25435 1.575 .741
SFRS6 AL031681 1.594 .526
Transcription regulation KLF4 BF514079 2.771 1.000
SOX18 AFFX-M27830_5 1.945 1.000
SOX7 AI808807 2.052 1.000
BHLHB2 NM_003670 2.051 1.000
SALL1 AU152837 1.773 1.000
766 Indomethacin Alters Choline Lipid Metabolism Glunde et al.
Neoplasia . Vol. 8, No. 9, 2006
indomethacin treatment in HMECs and breast cancer cells
was caused by the increased catabolic breakdown of PtdCho
by PLA2 and lysophospholipase and/or the inhibition of
GPC phosphodiesterase. Because 13C-labeled Cho was
not detected during indomethacin treatment of breast cancer
cells in short-term [1,2-13C]choline exposure but was sig-
nificantly increased following indomethacin treatment in
1H MR spectra, this increase in Cho most likely originated
from catabolic processes, such as PLD activation. In long-
term experiments, the fractional 13C enrichment in Cho was
constant following indomethacin treatment of breast cancer
cells, again indicating its catabolic origin. The decrease in
total PC and the absence of Cho in the 13C MR spectra of
short-term experiments following indomethacin treatment in
breast cancer cells suggest that indomethacin also up-
regulated the anabolic pathway, converting PC to CDP-
choline and PtdCho. The smaller total PC pool following
indomethacin treatment in breast cancer cells and the reduc-
tion in 13C enrichment of this PC pool were most likely a
combination of an increased anabolic rate and a faster
breakdown of unlabeled PtdCho, causing the dilution of 13C
label in the PC pool. These changes were not detected in
nonmalignant HMECs. In HMECs, no indomethacin-induced
differences were detected in the 13C enrichment of PC in
short-term or long-term experiments. In long-term [1,2-13C]-
choline exposure experiments, 13C enrichment of PtdCho
was significantly increased following indomethacin treatment
in HMECs, indicating that indomethacin resulted in an in-
creased anabolic flux of 13C label into membrane PtdCho
relative to a constant or decreased catabolic flux of 13C label
fromPtdCho by phospholipases. However, the absence of an
increase in fractional 13C enrichment in GPC in HMECs fol-
lowing indomethacin treatment suggests a contribution to
the total GPC increase from an unlabeled pool. In breast
cancer cells, this increase of PtdCho 13C enrichment follow-
ing indomethacin treatment was not observed to the same
extent. In summary, indomethacin appears to cause an in-
creased choline membrane turnover in breast cancer cells by
activating multiple phospholipases, as well as the anabolic
pathway. In HMECs, indomethacin resulted in an enhanced
anabolic pathway, but increased phospholipase activation
was not detected following indomethacin treatment.
Microarray analysis of gene expression revealed that
mRNA for none of the enzymes directly involved in choline
phospholipid metabolism was significantly overexpressed
or underexpressed following short-term indomethacin treat-
ment in MCF-12A HMECs and MDA-MB-231 breast cancer
cells. In contrast, our earlier study did detect differences in
choline phospholipid metabolism–related genes between
MCF-12A and MDA-MB-231 cells, explaining in part the sig-
nificantly different choline metabolite levels in these two cell
lines [5]. These data suggest that the changes in choline
phospholipid metabolites following indomethacin treatment
observed by MRS most likely occurred from changes in en-
zyme activity rather than from changes in enzyme expres-
sion, or indirectly from secondary effects through signaling
cascades. However, significant overexpression or under-
expression was detected in several genes following 2 hours
of indomethacin treatment in MCF-12A HMECs and human
MDA-MD-231 breast cancer cells, suggesting that indo-
methacin causes diverse changes at the transcriptional level.
Genes with altered expression following indomethacin treat-
ment were mostly different in the two cell lines. Change in the
expression common to both cell lines was observed for only
seven genes following the indomethacin treatment of HMECs
and breast cancer cells. This may imply mechanistic differ-
ences in the actions of indomethacin in HMECs and human
breast cancer cells.
The decrease in the mRNA expression of PTPN12 fol-
lowing indomethacin treatment in MCF-12A HMECs may play
a role in causing the changes observed in choline phospholipid
metabolism. Protein tyrosine phosphatases are involved
Table 2. (continued)
Function Gene Symbol Representative
Public ID
Fold Change Probability
Transcription regulation ZNF238 AJ223321 1.883 1.000
FUSIP1 AI954700 1.584 .985
FRBZ1 AW299558 1.527 .957
ADNP BG149849 1.553 .957
CHD1 AU155298 1.516 .952
TGFB1I4 AK027071 1.695 .942
SSA2 AU146655 1.610 .900
ZBTB11 NM_014415 1.592 .863
FOXQ1 AI676059 1.561 .832
GATA6 D87811 1.559 .775
BAZ1A NM_013448 1.575 .774
ZNF398 AI950078 1.471 .713
NFIB AI186739 1.557 .713
E2F3 NM_001949 1.553 .712
ZNF148 NM_021964 1.539 .630
JUNB NM_002229 1.578 .615
CREBL2 NM_001310 1.540 .530
ARID1A NM_018450 1.528 .502
EIF1AX AL079283 1.675 .971
Transport ZNF238 AJ223321 1.883 1.000
SLC16A1 AL162079 1.552 .659
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Table 3. Significantly Differentially Expressed Genes Following Indomethacin Treatment in MDA-MB-231 Breast Cancer Cells, by Function.
Function Gene Symbol Representative Public ID Fold Change Probability
Angiogenesis regulation RHOB AI263909 2.032 1.000
ANGPTL4 NM_016109 2.546 1.000
IL8 NM_000584 1.824 .995
Apoptosis regulation RHOB AI263909 2.032 1.000
ANGPTL4 NM_016109 2.546 1.000
GADD45B NM_015675 1.640 1.000
BIRC3 U37546 1.696 .998
Blood coagulation SERPINE1 NM_000602 2.067 1.000
PLAU NM_002658 1.736 .987
THBD NM_000361 1.509 .506
Cell adhesion NEDD9 U64317 2.061 1.000
RHOB AI263909 2.032 1.000
IL8 NM_000584 1.824 .995
Cell cycle regulation DUSP1 NM_004417 2.856 1.000
NEDD9 U64317 2.061 1.000
RHOB AI263909 2.032 1.000
SNF1LK NM_030751 1.834 1.000
IL8 NM_000584 1.824 .995
DUSP6 BC005047 1.626 .930
PLK2 NM_006622 1.550 .738
Cell growth regulation NEDD9 U64317 2.061 1.000
Cell motility IL8 NM_000584 1.824 .995
Chemotaxis IL8 NM_000584 1.824 .995
PLAU NM_002658 1.736 .987
Choline phospholipid metabolism JUNB NM_002229 3.265 1.000
RHOB AI263909 2.032 1.000
EDN1 NM_001955 2.999 1.000
IL8 NM_000584 1.824 .995
CSF2 M11734 1.622 .977
NGFB NM_002506 1.610 .966
Cytoskeleton organization NEDD9 U64317 2.061 1.000
Development CSF2 M11734 1.622 .977
NGFB NM_002506 1.610 .966
SNAI2 AI572079 1.627 .923
FZD7 NM_003507 1.557 .856
NKX3-1 AF247704 1.514 .577
Differentiation SNF1LK NM_030751 1.834 1.000
GADD45B NM_015675 1.640 1.000
IL11 NM_000641 1.515 .504
Endocytosis TFRC N76327 1.770 .909
Endosome-to-lysosome transport RHOB AI263909 2.032 1.000
Hypoxia response ANGPTL4 NM_016109 2.546 1.000
Immune response GBP1 AW014593 1.753 .999
IL6ST AB015706 1.642 .778
Ion homeostasis TFRC N76327 1.770 .909
ATP8B1 BG290908 1.552 .693
Lipid metabolism ANGPTL4 NM_016109 2.546 1.000
NR2F2 AL037401 1.633 .982
ATP8B1 BG290908 1.552 .693
Not determined AMIGO2 AC004010 2.553 1.000
VMP1 BF674052 3.353 1.000
C6orf145 AK024828 1.729 .999
TXNIP AA812232 1.765 .998
LBH NM_030915 1.665 .985
TPD52L1 NM_003287 1.517 .950
DKFZP566D1346 AL136717 1.625 .944
ZFP36L1 BE620915 1.596 .864
NET1 NM_005863 1.540 .622
Proliferation regulation EDN1 NM_001955 2.999 1.000
IL8 NM_000584 1.824 .995
TOB1 BF240286 1.718 .910
ADAMTS1 AF060152 1.726 .898
KLF4 NM_004235 1.811 .855
IL11 NM_000641 1.515 .504
Protein dephosphorylation DUSP6 BC005047 1.626 .930
PPM2C BG542521 1.574 .735
DUSP1 AA530892 1.527 .655
Protein phosphorylation SNF1LK NM_030751 1.834 1.000
ARK5 NM_014840 1.668 .988
PLK2 NM_006622 1.550 .738
Protein transport RHOB AI263909 2.032 1.000
ARL7 AW450363 1.651 .991
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in signaling cascades regulating PtdCho-specific PLC [32] or
PtdCho-specific PLD [33]. Protein tyrosine phosphatase
inhibition with vanadate induced PC production through
PtdCho-specific PLC [32] or PLD [33] activation. Decreased
PTPN12 gene expression could potentially activate PtdCho-
specific PLC and PLD. Decreased mRNA expression of
MAP4K4 [34] in MCF-12A HMECs following indomethacin
treatment may impact on choline phospholipid metabolism
through c-Jun N-terminal kinase [34]. Decreased PRKCI ex-
pression in MCF-12A HMECs following indomethacin treat-
ment can potentially downregulate group IV cytosolic PLA2
[35] and PtdCho-specific PLD isoform 2 [36]. These effects in
gene expression in signaling pathways potentially affecting
phospholipases are inconclusive in light of MCF-12A 13C MR
data demonstrating no significant activation of phospho-
lipases. The significant decrease in UGCG [37] mRNA levels
following indomethacin treatment in MCF-12A HMECs can
alter choline phospholipid metabolism by increasing the avail-
ability of cellular ceramide and sphingomyelin (SM) pools,
which may change the SM–PtdCho balance maintained by
sphingomyelinase and SM synthase [38]. The actions of
sphingomyelinase and SM synthase would also affect cellular
PC levels.
In human MDA-MB-231 breast cancer cells, significantly
reduced IL8 expression levels following indomethacin treat-
ment may indicate decreased PtdCho-specific PLD or PLC
activity. In cells of the immune system, IL8 stimulation can
elicit increased PtdCho-specific PLD or PLC activity through
IL8 receptors [39]. In bronchial epithelial cells, the activation
of PtdCho-specific PLD1 and PLD2 was shown to participate
in a signaling cascade, resulting in IL8 secretion from these
cells [40]. Increased NGFB polypeptide expression in MDA-
MB-231 breast cancer cells treated with indomethacin may
be related to the observed increase in choline membrane
turnover because nerve growth factor was demonstrated to
enhance PtdCho biosynthesis by increasing diacylglycerol
cholinephosphotransferase activity [41]. In breast cancer
cells, indomethacin-induced NGFB expression may have
activated PtdCho biosynthesis, which is consistent with our
13C MR data, demonstrating an increased choline mem-
brane turnover in indomethacin-treated breast cancer cells
by activating the anabolic pathway. Overexpression of
granulocyte–macrophage colony-stimulating factor (CSF2)
in indomethacin-treated MDA-MB-231 breast cancer cells
may be related to the upregulation of PtdCho-specific PLD,
as previously demonstrated in human neutrophils [42], con-
sistent with the upregulation of PtdCho-specific phospho-
lipase activity detected in our 13C MRS data. The increased
expression of RHOB in indomethacin-treated MDA-MB-
231 breast cancer cells may be involved in stimulating
PtdCho-specific PLD activity, as previously shown [43], con-
sistent with the activation of phospholipases observed in our
13C MRS data. Indomethacin treatment resulted in EDN1
(or ET1) overexpression in human MDA-MB-231 breast
Table 3. (continued)
Function Gene Symbol Representative Public ID Fold Change Probability
Protein ubiquitination IBRDC2 AI953847 1.737 .999
BIRC3 U37546 1.696 .998
Proteolysis PLAU NM_002658 1.736 .987
TFRC N76327 1.770 .909
ADAMTS1 AF060152 1.726 .898
Proton transport ATP5I BC003679 1.507 .944
Signal transduction NEDD9 U64317 2.061 1.000
TMEPAI NM_020182 2.653 1.000
EDN1 NM_001955 2.999 1.000
SMAD7 NM_005904 1.943 1.000
BIRC3 U37546 1.696 .998
IL8 NM_000584 1.824 .995
ARL7 AW450363 1.651 .991
PLAU NM_002658 1.736 .987
NR2F2 AL037401 1.633 .982
CSF2 M11734 1.622 .977
NGFB NM_002506 1.610 .966
ADAMTS1 AF060152 1.726 .898
FZD7 NM_003507 1.557 .856
IL6ST AB015706 1.642 .778
PLK2 NM_006622 1.550 .738
IL11 NM_000641 1.515 .504
Transcription regulation BHLHB2 BG326045 3.198 1.000
JUNB NM_002229 3.265 1.000
SMAD7 NM_005904 1.943 1.000
CITED2 NM_006079 1.799 1.000
NR2F2 AL037401 1.633 .982
SNAI2 AI572079 1.627 .923
KLF4 NM_004235 1.811 .855
NKX3-1 AF247704 1.514 .577
ARID5B BG285011 1.496 .518
JUN NM_002228 4.347 .514
Transport SLC19A2 AF153330 1.535 .765
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cancer cells.EDN1 is a potent vasoconstrictor peptide, which
can also induce proliferation, differentiation, apoptosis, and
matrix metalloprotease expression [44]. In several cell
types, such as fibroblasts, myocytes, and osteoblasts, EDN1-
mediated activation of PtdCho-specific phospholipases D, C,
and A2 was demonstrated [45–48]. EDN1-evoked PtdCho-
PLD and PtdCho-PLA2 activation stimulates the release of
arachidonic acid and prostaglandins [47,48]. In breast can-
cer cells, indomethacin-induced EDN1 expression most likely
activated PtdCho-specific phospholipases, consistent with
our 13C MR data, demonstrating the activation of PtdCho-
specific phospholipases.
Indomethacin treatment in human MDA-MB-231 breast
cancer cells, as well as in MCF-12A HMECs, resulted in the
overexpression of JUNB, which was more pronounced in
the breast cancer cell line. JUNB belongs to the Jun gene
family of the activating protein-1 transcription factors involved
in cell growth [49], differentiation [50], cell cycle regulation
[51], and, possibly, neoplastic transformation [49]. Over-
expression of JUNB can repress transcription [52]. JUNB
transcription can be activated downstream of PtdCho degra-
dation during the G1 phase of the cell cycle [53]. Thus, JUNB
overexpression may be the result of indomethacin-driven
phospholipase activation, which was more pronounced in
MDA-MB-231 breast cancer cells than in MCF-12A HMECs,
according to 13C MRS data.
Previous studies with MCF-7 breast cancer cells have
reported that choline transport is the rate-limiting step in PC
synthesis in this breast cancer cell line [7]. Although arachi-
donic acid has been linked to the activation of the sodium-
dependent high-affinity choline transporter [54], the specific
molecular choline transporters responsible for the transport
of Cho across the plasmamembranes of HMECs and human
breast cancer cells have not yet been identified. The micro-
array gene expression analysis performed in our previous
study [5] demonstrated that no significant differences in
choline transporters were detected between HMECs and
breast cancer cells. Indomethacin treatment did not alter
gene expression levels in choline transporters in either
HMECs or human breast cancer cells. However, it is possible
that posttranscriptional changes in choline transporter ac-
tivities may have been caused by indomethacin treatment.
Indomethacin appears to have multiple effects on the
gene expression of human breast cancer cells, some of which
may influence PC metabolism indirectly through signaling
cascades, such as protein kinases, protein phosphatases, or
signaling peptides. Indomethacin-induced CSF2, RHOB,
and EDN1 overexpression mediating the activation of mul-
tiple phospholipases matches well with the 13C data obtained
from breast cancer cells; a strong activation of phospholi-
pases was observed with indomethacin treatment in breast
cancer cells, but not to the same extent as in HMECs.
In this study, distinct differences were identified for indo-
methacin-mediated changes in choline metabolite profile in
nonmalignant HMECs versus breast cancer cells. Indo-
methacin treatment resulted in an increased choline mem-
brane turnover by activating multiple phospholipases, as well
as by enhancing the anabolic pathway in breast cancer cells.
In HMECs, however, indomethacin predominantly increased
the rate of anabolic choline membrane metabolism. The
changes in choline metabolite profile following indomethacin
treatment were not caused by an overexpression or under-
expression of the enzymes involved in choline metabolism.
The effects of indomethacin treatment on the choline metab-
olite profile of HMECs and breast cancer cells could well be
mediated by a combination of secondary effects or signaling
cascades. Microarray analysis of gene expression revealed
that indomethacin treatment in HMECs and breast cancer
cells caused diverse changes at the transcriptional level,
which were mostly nonuniform for HMECs and breast cancer
cells. This may imply mechanistic differences in the effects of
indomethacin treatment on HMECs versus breast cancer
cells. Candidate genes mediating the indomethacin-induced
changes in choline phospholipid metabolism include IL8,
NGFB, CSF2, RHOB, EDN1, and JUNB in breast cancer
cells. The characteristic changes in choline membrane me-
tabolism during indomethacin treatment observed here sup-
port further investigation of the role of NSAIDs in cancer
prevention and in the treatment of primary and metastatic
diseases. The application of 13CMR spectroscopy, combined
with microarray gene expression analysis, was shown to be a
useful tool in characterizing distinct mechanisms of such
NSAID treatment in human breast cancer.
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